Selumetinib, a small molecule MEK inhibitor, is an anti-cancer drug in Phase 2 development in a range of tumors. It was licensed from Array to AstraZeneca.
The study demonstrated a rise in survival rate in patients who were given selumetinib in combination with docetaxel versus docetaxel alone.
The secondary endpoints of progression-free survival, objective response rate, and alive and progression-free at 6 months showed improvement in favor of selumetinib in combination with docetaxel versus docetaxel alone.
AstraZeneca is also set to complete Phase 2 trial with selumetinib in combination with dacarbazine.